BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 12168863)

  • 1. Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy.
    Fisher M; Yang LX
    Anticancer Res; 2002; 22(3):1737-54. PubMed ID: 12168863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polysaccharide K and Coriolus versicolor extracts for lung cancer: a systematic review.
    Fritz H; Kennedy DA; Ishii M; Fergusson D; Fernandes R; Cooley K; Seely D
    Integr Cancer Ther; 2015 May; 14(3):201-11. PubMed ID: 25784670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polysaccharide-K (PSK) in cancer--old story, new possibilities?
    Sun C; Rosendahl AH; Wang XD; Wu DQ; Andersson R
    Curr Med Chem; 2012; 19(5):757-62. PubMed ID: 22204346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of research on the protein-bound polysaccharide (polysaccharopeptide, PSP) from the mushroom Coriolus versicolor (Basidiomycetes: Polyporaceae).
    Ng TB
    Gen Pharmacol; 1998 Jan; 30(1):1-4. PubMed ID: 9457474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immunomodulator PSK induces in vitro cytotoxic activity in tumour cell lines via arrest of cell cycle and induction of apoptosis.
    Jiménez-Medina E; Berruguilla E; Romero I; Algarra I; Collado A; Garrido F; Garcia-Lora A
    BMC Cancer; 2008 Mar; 8():78. PubMed ID: 18366723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological mechanism and clinical effect of protein-bound polysaccharide K (KRESTIN(®)): review of development and future perspectives.
    Maehara Y; Tsujitani S; Saeki H; Oki E; Yoshinaga K; Emi Y; Morita M; Kohnoe S; Kakeji Y; Yano T; Baba H
    Surg Today; 2012 Jan; 42(1):8-28. PubMed ID: 22139128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of adjuvant immunochemotherapy using protein-bound polysaccharide-K on overall survival of patients with gastric cancer.
    Tanaka H; Muguruma K; Ohira M; Kubo N; Yamashita Y; Maeda K; Sawada T; Hirakawa K
    Anticancer Res; 2012 Aug; 32(8):3427-33. PubMed ID: 22843926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PSK, a protein-bound polysaccharide, overcomes defective maturation of dendritic cells exposed to tumor-derived factors in vitro.
    Okuzawa M; Shinohara H; Kobayashi T; Iwamoto M; Toyoda M; Tanigawa N
    Int J Oncol; 2002 Jun; 20(6):1189-95. PubMed ID: 12011998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulation and anti-cancer activity of polysaccharide-protein complexes.
    Ooi VE; Liu F
    Curr Med Chem; 2000 Jul; 7(7):715-29. PubMed ID: 10702635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation by the protein-bound polysaccharide PSK (krestin) of cytotoxic lymphocytes that act on fresh autologous tumor cells and T24 human urinary bladder transitional carcinoma cell line in patients with urinary bladder cancer.
    Mizutani Y; Yoshida O
    J Urol; 1991 May; 145(5):1082-7. PubMed ID: 2016797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA antigen as predictive index for the outcome of breast cancer patients with adjuvant immunochemotherapy with PSK.
    Yokoe T; Iino Y; Takei H; Horiguchi J; Koibuchi Y; Maemura M; Ohwada S; Morishita Y
    Anticancer Res; 1997; 17(4A):2815-8. PubMed ID: 9252721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PSK as a chemopreventive agent.
    Kobayashi H; Matsunaga K; Fujii M
    Cancer Epidemiol Biomarkers Prev; 1993; 2(3):271-6. PubMed ID: 8318880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of immunopotentiation activity by a protein-bound polysaccharide, PSK (review).
    Sakagami H; Aoki T; Simpson A; Tanuma S
    Anticancer Res; 1991; 11(2):993-9. PubMed ID: 2064356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro reactivity to a protein-bound polysaccharide PSK of peripheral blood lymphocytes from patients with gastrointestinal cancer.
    Sugimachi K; Maehara Y; Kusumoto T; Okamura T; Korenaga D; Kohnoe S; Baba H; Anai H
    Anticancer Res; 1995; 15(5B):2175-9. PubMed ID: 8572620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of effector cell activities in mice bearing syngeneic plasmacytoma X5563 by a biological response modifier, PSK.
    Matsunaga K; Iijima H; Aota M; Oguchi Y; Fujii T; Yoshikumi C; Nomoto K
    J Clin Lab Immunol; 1992 Jan; 37(1):21-37. PubMed ID: 1339233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of gene expression for immunomodulating cytokines in peripheral blood mononuclear cells in response to orally administered PSK, an immunomodulating protein-bound polysaccharide.
    Kato M; Hirose K; Hakozaki M; Ohno M; Saito Y; Izutani R; Noguchi J; Hori Y; Okumoto S; Kuroda D
    Cancer Immunol Immunother; 1995 Mar; 40(3):152-6. PubMed ID: 7728773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimetastatic effects of PSK (Krestin), a protein-bound polysaccharide obtained from basidiomycetes: an overview.
    Kobayashi H; Matsunaga K; Oguchi Y
    Cancer Epidemiol Biomarkers Prev; 1995; 4(3):275-81. PubMed ID: 7606203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Induction of manganese superoxide dismutase by an immunopotentiator as a mechanism of inhibiting of malignant progression of murine tumor cells].
    Habelhah H
    Hokkaido Igaku Zasshi; 1998 Sep; 73(5):519-29. PubMed ID: 9846281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunochemotherapy benefits in gastric cancer patients stratified by programmed death-1 ligand-1.
    Hsu JT; Hsu CS; Le PH; Chen TC; Chou WC; Lin CY; Yeh TS
    J Surg Res; 2017 May; 211():30-38. PubMed ID: 28501128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant PSK immunotherapy in patients with carcinoma of the nasopharynx.
    Go P; Chung CH
    J Int Med Res; 1989; 17(2):141-9. PubMed ID: 2656331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.